Oncolytics Biotech updates patent portfolio for pelareorep

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. COF
10. GOOGL

Go back to Oncolytics Biotech updates patent portfolio for pelareorep

Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update

October 12, 2026 4:05 PM EDT

New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near term

Three patent applications are pending, including two method of use with one expected to be converted to a Track One application this quarter

Company expects to add a new composition of matter patent covering next generation pelareorep

SAN DIEGO, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (Oncolytics or the Company), a clinical-stage immunotherapy... More